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ABSTRACT 
This thesis research focuses on the interaction of gold(I) thiolates with the disulfide 
bonds in proteins, using insulin as a model protein. Insulin contains three disulfide bonds 
that can break apart during thiol-disulfide exchange reactions. The goal of this research 
was to compare the reactivity of aromatic thiols and gold(I) thiolates in thiol-disulfide 
exchange reactions with insulin. When the disulfide bonds in insulin are cleaved, a 
suspension of the beta chain particles forms, which scatters 650 nm light, therefore 
making it convenient to monitor the reaction using UV-Vis spectroscopy. The rate of 
formation of the colloidal suspension is taken to be directly proportional to the rate of 
disulfide bond breakage, as reported by Lees, et al.1 who studied the ability of aromatic 
thiols to catalyze the reaction of dithiothreitol (DTT) and insulin. The project began by 
measuring the relative rate of the reaction between 4-mercaptobenzoic acid, DTT and 
insulin vs DTT and insulin, which was also done by the Lees research group. All 
reactions were conducted at room temperature in pH 6.5 phosphate buffered solution. The 
rate of disulfide bind cleavage in the reaction of 4-mercaptobenzoic acid, DTT and 
insulin was 1.7 times faster than the reaction of DTT and insulin. This is consistent with 
the relative rate of 1.6 reported by Lees, et al.1 and provided confidence that using the 
light scattering technique described by Lees, et al. to monitor the reactions with insulin 
was a viable method in our lab. Another experiment was conducted to see whether 4-
mercaptobenzoic acid would react with insulin by itself; however, this reaction did not 
produce a colloidal suspension within a 24-hour period of time, which suggests that 4-
mercaptobenzoic acid does not cleave the disulfide bonds in insulin in the absence of 
DTT. The reaction between 2-mercaptopyridine (Spy), DTT and insulin was also 
investigated, and it was determined that 2-mercaptopyridine behaves similarly to 4-
mercaptobenzoic acid. The next set of experiments was conducted to determine the effect 
of replacing aromatic thiols with gold(I) thiolates. Addition of Et3PAu(Spy) to a solution 
of DTT and insulin caused cleavage of the disulfide bonds in insulin, as observed by an 
increase of light scattering at 650 nm. The shape of the absorbance (intensity of light 
scattering) vs. time graph suggests two or more possible competing mechanisms. This is 
further supported by the observation that Et3PAu(Spy) reacts with DTT and insulin 
separately. In the reaction of Et3PAuSpy and insulin, there is formation of a colloidal 
suspension while in the reaction between Et3PAuSpy and DTT, 2-mercaptopyridine is 
produced, as evidenced by UV-Vis and 1H NMR spectroscopy. The findings of the study 
suggest that Et3PAu(Spy) undergoes a thiol disulfide exchange reaction with insulin, 
causing precipitation of the β-chains. Furthermore, this reaction occurs in the absence of 
DTT, which is different than the reactivity of aromatic thiols. It is not known whether the 
Et3PAu moiety binds to one of the insulin chains or whether further reaction occurs. 
Additional studies should be done to deduce the mechanism of the reaction. Et3PAuCl 
was also shown to react with insulin, resulting in the formation of a precipitate. Since 
Et3PAuCl cannot undergo thiol disulfide exchange, it is suggested that Et3PAuCl interacts 
with other donor atoms such as histidine residues in insulin, instead of interacting with 
the disulfide bonds, but further studies should be done to deduce the mechanism of the 
reaction.
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INTRODUCTION 
	
Insulin contains three disulfide bonds that can break apart during thiol-disulfide exchange 
reactions, forming a suspension of the beta chain particles, which scatters 650 nm light, 
therefore making it convenient to monitor the reaction using UV-Vis spectroscopy, where 
the rate of formation of the colloidal suspension is taken to be directly proportional to the 
rate of disulfide bond breakage. Aromatic thiols have been shown to increase the rate of 
disulfide bond breakage in the reaction between dithiothreitol (DTT) and insulin, where 
DTT and the aromatic thiol can act as redox buffers. A redox buffer is composed of a 
redox couple; in this case a reducing thiol and corresponding oxidized disulfide. A redox 
buffer is analogous to an acid-base buffer in that a species that is in abundance in solution 
will be neutralized by the corresponding component of the redox couple2. The same way 
that the conjugate acid in a buffer neutralizes an added base, thiol reduces an added 
oxidant and disulfide oxidizes a reduced species. A redox buffer is an aide in protein 
folding. In terms of physiology, the ratio of thiol to disulfide is an important factor in 
helping to maintain redox homeostasis for healthy functioning of the organism. For 
example, glutathione (GSH) is the most abundant antioxidant in aerobic cells, present in 
micromolar concentrations in bodily fluids and millimolar concentrations in tissue3. GSH 
is critical for protecting the brain from oxidative stress, with a normal percent of GSH 
compared to the corresponding disulfide (GSSG) of 98%3. This ratio of GSH/GSSG is 
reduced in neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s 
disease3. The abundant research that has been conducted on glutathione ratios in humans 
shows that the ratio is an important factor in the development of disease. Thus, it is 
important to study redox buffers as potential ways of understanding the mechanisms of 
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these diseases. The following study was conducted to observe the effect of gold thiolates 
on biological disulfides, using insulin as a model protein disulfide. It was predicted that 
gold thiolates might act as a redox buffer, much in the same way that an aromatic thiol 
would in the reaction between DTT and insulin. 
Goals of Research 
The major question of this study is concerned with how gold thiolates may be interacting 
with biological disulfide proteins such as insulin. The hypothesis entails the use of gold 
thiolate as a redox buffer, much in the same way that an aromatic thiol/thiolate can act as 
a redox buffer in the reaction between insulin and DTT (where DTT also acts as a redox 
buffer). The Lees research group has done extensive research on the aspects of a protein 
folding redox buffer that would be most advantageous for the rate and yield of protein 
folding, and has specified the following criteria for advantages to the redox buffer: 
 
1) Low thiol pKa (strongly acidic thiol, weakly basic thiolate-close to physiological 
pH), a pKa of approximately 1 unit less than the pH of the solution has been 
found to be optimal for protein folding, because of the enhanced reactivity of the 
thiolate4 
2) Low reduction potential (allows the redox buffer to exist as a nearly 50:50 
mixture of thiol and disulfide for efficient protein folding)4 
3) Dithiol over a monothiol (dithiols discourage forming long-lived mixed disulfides 
between the folding catalyst and the protein of interest) 
4) Aromatic over aliphatic increases the rate of folding by at least three times 
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The Lees research group had published a paper in 2012 on the synthesis and protein 
folding rates of aromatic dithiols, combining the two advantages (dithiol and aromatic) to 
make a power duo5, but they have not attempted to do the same for metals, such as gold. 
Before such attempts are made it is important to see if a gold thiolate would react with a 
protein disulfide and if so, if it would act as a redox buffer. The plan is to conduct a set of 
UV-Vis and 1H NMR experiments to investigate the reactions of gold complexes, thiols 
and insulin to observe possible interactions between the reactants that would hint at the 
possibility of gold thiolate acting as a redox buffer. Starting with the reaction between 
insulin, DTT and an aromatic thiol, the goal is to replace the aromatic thiol with a gold 
thiolate and observe the interaction. Along the way, several other experiments will be 
conducted, such as the reaction between DTT and a gold thiolate, to look at possible side 
reactions. 
 
Gold in Medicine 
	
Gold has been used medicinally to treat various diseases for many centuries. The use of 
gold dates as far back as 2500 BC, the earliest application of gold as a therapeutic in 
China6,7. The modern interest in gold is attributed to the discovery by Robert Koch in 
1890 that gold cyanide inhibits the growth of Tubercle bacillus, the bacterium that causes 
tuberculosis in humans6,7. Despite the lack of experimental evidence and the toxicity of 
the compound, the “gold decade” followed (1925-1935), in which intravenously 
administered gold(I) thiolate salts were used for the treatment of tuberculosis6,7. During 
this time, gold therapy was also found to reduce joint pain in a group of non-tubercular 
patients, which led Jacques Forestier, a French physician, to research the use of gold 
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compounds as a treatment for rheumatoid arthritis6,7. Subsequently, in 1960 a trial 
concluded that gold drugs have a beneficial effect for the treatment of rheumatoid 
arthritis6,7. Some gold thiolate drugs that were first introduced in the 1920’s are still used 
today (Figure 1). These drugs primarily slow the progression of disease. Auranofin 
(Figure 1.3) is an orally active drug. Despite early indications that auranofin offered 
significant advantages over injectable Au(I) thiolates, it was later proven that auranofin 
is, in fact, less effective6,7. Because of this, oral gold is now rarely used clinically6,7. 
Figure 1: Examples of gold(I) drugs used for the treatment of rheumatoid arthritis (1) 
sodium aurothiomalate (Myocrisin), (2) aurothioglucose (Solganol), (3) tetraacetyl-B-d-
thioglucose gold(I) triethylphosphine (auranofin). The 1:1 Au-S drugs (1 and 2) are 
polymers6. 
 
Gold Thiolates as Treatment for Rheumatoid Arthritis 
Specifically, gold thiolates are used to treat rheumatoid arthritis, which is a chronic 
inflammatory disease characterized by the migration of activated phagocytes and 
leukocytes into synovial tissue, which causes progressive destruction of cartilage and 
bone and joint swelling6,7. There is evidence that gold thiolates have several different 
ways they help treat the disease, where most cases involve interaction with protein Cys 
(or Sec) residues6,7. Recent studies on gold thiolate mechanisms have focused on their 
effects on macrophage signal transduction and the induction of inflammatory 
cytokines6,7. Cytokines are low molecular weight peptides, proteins or glycoproteins6,7. 
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Gold compounds can play a role in each of the phases of the immune reaction, such as the 
initiation stage6,7. During this stage, gold is taken up by macrophages and inhibits antigen 
processing6,7. This likely happens by binding peptide antigens that contain cysteine and 
methionine residues6,7. Gold then accumulates, in the form of S-Au(I)-S, in the lysosomes 
of synovial cells and macrophages, forming aurosomes (gold laden deposits)6,7. At the 
level of transcription, gold(I) drugs downregulate a range of proinflammatory genes by 
inhibiting transcriptional activities of the NF-kB and AP-1 (Jun/Fos) transcription 
factors7. In general, AP-1 controls the expression of genes for collagenase and the 
cytokine IL-2, and NF-kB controls transcription of other inflammatory mediators, 
including TNF-α, IL-1, and IL-67. Additionally, gold drugs act at the T-cell level, and 
have been shown to inhibit osteoclast bone resorption, recently attributed to the inhibition 
of the cathepsins6,7. Rheumatoid arthritis patients also have elevated levels of copper that 
can be correlated to the severity of the disease6,7. This might be because gold drugs could 
interfere with copper homeostasis by binding Cu(I) responsive transcription factors and 
other Cu(I) transport proteins6,7.  
 
Gold drugs are classified as DMARDS (disease-modifying anti-rheumatic drugs). Despite 
the fact that DMARDS are one of the only ways to place the inflammatory disease in 
remission, they are slow acting, sometimes requiring 3-6 months for patients to 
experience improvement in joint function and reduction in swelling8.  
 
Other Medicinal Uses of Gold 
In addition to being used as rheumatoid arthritis medications, Au(I) and Au(III) 
compounds have also been used and designed with an aim of targeting cellular 
components that are implicated at the onset or progression of cancers, as well as viral and 
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parasitic diseases6,7. In the mid 1980’s auranofin (Figure 1.3) was shown to inhibit the 
growth of cultured tumor cells6. Since then, a large variety of Au(I) and Au(III) 
complexes has been developed that show some kind of inhibition of tumor growth and 
have been shown to have potential as cancer treatments6. In addition, various Au(I) 
antitumor compounds, including auranofin, have been shown to overcome resistance to 
cisplatin and other anticancer drugs7. Many mechanistic studies indicate mitochondria as 
the biological targets for gold antitumor compounds since mitochondria play a key role in 
the regulation of apoptosis and the regulation of the intracellular redox state7.  
 
Gold-based compounds also showed early promise as a less toxic and less drug resistant 
version of an AIDS cure6. A variety of Au(I) and Au(III) compounds have been 
investigated as anti-HIV agents6. Gold-based compounds also offer great potential in the 
field of affordable antiparasitic drugs6. This is because they can bind thiol and selenol 
proteins that have been identified as drug targets in trypanosomes (African sleeping 
sickness, Chagas’ disease and leishmaniasis), malaria-causing plasmodia, and 
schistomiasis6. In conclusion, there is great potential for application of the gold complex 
mechanisms for treatment of a variety of diseases, and for the design of new gold 
complexes for diseases with the same target complexes.  
 
Gold Compounds 
Gold(I) (5d10) is a large ion with a low charge and is a “soft” Lewis acid, therefore 
forming its most stable complexes with “soft” ligands such as CN, S-donors, P-donors 
and Se ligands7. Linear, two-coordination is most common for gold(I)7. The highest 
affinity gold(I) has is for thiols with the lowest pKa values7.   
		 7 
There are examples in the literature of gold(I) complexes facilitating disulfide bond 
cleavage in biologically relevant systems9,10. Early studies on auranofin (Figure 1.3) 
show that its highly reactive nature towards protein thiols limits its antitumor activity in 
vivo6. Subsequently, the development of Au(I) complexes with chelated diphosphines 
such as [Au(dppe)2]Cl (Figure 2) began with the goal of reducing the high thiol reactivity 
of auronofin and similar compounds. The behavior of this compound is consistent with 
that of the class of antitumor agents known as delocalized lipophilic cations (DLCs), that 
accumulate in the mitochondria of tumor cells driven by one of the characteristic features 
of some cancer cells- an elevated mitochondrial membrane potential6. It was found that 
the high lipophilicity of these compounds results in severe toxicity as a consequence of 
the inability of the compounds to differentiate between tumorigenic and non-tumorigenic 
cells, concentrating in both and causing general membrane permeabilization6. A 
compound was designed to retain the lipophilic cationic properties of the tetrahedral bis-
chelated complexes that allow accumulation into the mitochondria, but reduce the 
cytotoxicity of the compound, so it can be used as an anti-tumor agent1. This compound 
was [Au(d2pypp)2]Cl, and recent findings have shown that the compound is selectively 
toxic to breast cancer cells but not normal breast cells. 
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Figure 2: Examples of lipophilic cationic gold(I) antitumor compounds6. 
 
Similar compounds were used as the focus of this investigation. Specifically, Et3PAuCl, 
Et3PAuSpy (where py is a 2-pyridyl group), and Et3PAuSba (where ba is a benzoic acid 
group) (Figure 3).  
 
 
Figure 3: From left to right: structures of Et3PAuSpy, Et3PAuSba and Et3PAuCl 
respectively. 
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Et3PAuSpy has been shown to have antitumor effects in vivo (mice) and has also been 
shown to have a similar cytotoxicity to auranofin in vitro (P388 leukemia cells)11. 
Et3PAuCl was less cytotoxic in vitro but had the same maximally tolerated dose in tumor 
bearing mice, on a daily x5 ip (intraperitoneal injection) regimen11. Between the two 
compounds, Et3PAuSpy had a larger antitumor effect (46% median life span (ILS) 
increase in mice inoculated ip with 106 P388 leukemia cells, given ip on days 1-5) versus 
Et3PAuCl (36% ILS increase), where an ILS value of ≥40% represents cell kill sufficient 
to result in net reduction in tumor cell burden at the end of therapy; with a level of 
significance of p≤0.0511. Early mechanistic studies provided evidence that Et3PAuCl 
affects mitochondrial function and these results are consistent with an antitumor 
mechanism involving the induction of mitochondrial-dependent apoptosis pathways7. 
It is of interest to note that some studies have hypothesized that the more reactive the 
gold compound is towards disulfide bonds, the more toxic it probably is9. This hypothesis 
stems from the observation that the more a compound is like auranofin structurally, the 
more easily it breaks disulfide bonds and the likelihood that the biological activity of the 
compound will be similar to auranofin increases, therefore making the compound 
supposedly more toxic.  
Thiols 
The thiols used in this study include dithiothreitol (DTT), 4-mercaptobenzoic acid (Sba), 
and 2-mercaptopyridine (Spy) (Figure 4). 
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Figure 4: Thiols used in this study from left to right: dithiothreitol (DTT) (pKa=9.2, 
10.1), 4-mercaptobenzoic acid (Sba) (pKa=5.95), and 2-mercaptopyridine. 
 
It is known that 4-mercaptobenzoic acid increases the activity of protein disulfide 
isomerase (PDI) by a factor of three12. PDI is a eukaryotic enzyme that has many 
functions during the folding of disulfide-containing proteins (Figure 5)12. In terms of a 
mechanism, PDI functions in the same way as an aromatic thiol when in solution with a 
protein disulfide. It is also known that 4-mercaptobenzoic acid catalyzes the reaction 
between insulin and DTT1. PDI contains two active sites, each of which has a CXXC 
motif, where X is any amino acid and C is cysteine4. The two cysteines form a 14-
membered ring upon oxidation to the disulfide4.  
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Figure 5: Structure of protein disulfide isomerase (PDI). Backbones are indicated as 
rounded ribbons, which are part of α-helices or β-sheets. The string-like filaments are 
parts of loops and turns (different kind of protein organisation). Each color is a different 
chain. The chains come together to form PDI. Picture constructed using Chimera viewing 
software (PDB file:2BJX, protein disulfide isomerase) 
 
DTT itself can act as a buffer by having a mix of reduced thiol DTT and oxidized 
disulfide DTT, which forms a redox buffer, a mix of thiol (RSH) and corresponding 
disulfide (RSSR)1,12. Dithiols, like DTT, are proposed to improve protein folding by 
shortening the lifetime of kinetically stable mixed disulfide formed between the protein 
and the small molecule thiol13. Having two thiols makes it easier for DTT to displace the 
mixed disulfide intramolecularly instead of intermolecularly, as is the case for 
monothiols, where intramolecular displacement is proposed to be more rapid13. DTT has 
been studied extensively for its reducing capabilities when in contact with disulfides. As 
the reduced DTT is not UV-active, one can use the oxidized DTT formed in the process 
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of thiol-disulfide exchange to quantify the number of disulfide bonds broken by 
measuring the absorbance at 310 nm, where the molar absorption of DTT is 40% of its 
maximum absorbance14. The number of SH groups per mole protein was measured by 
rapid gel filtration with the method of Ellman (see source 10 citation 8). DTT has also 
been studied for its proposed activities in stimulating the insulin receptor/kinase, which is 
the initial event of insulin action (binding of insulin to its receptor on the cell surface of 
target cells15. Some studies focused on the calorimetric measurements of the reduction of 
insulin by DTT, which allows to approximate the number of protons attached to cysteine 
residues in insulin after reduction, thereby approximating the degree to which the 
disulfide bonds in insulin have been reduced16,17. 
An advantage that PDI has over monothiols is the availability of two thiols at each active 
site. There is a proposed advantage for dithiols that has been termed the “escape 
mechanism” that allows the dithiol to discourage the formation of long-lived mixed 
disulfides between the folding catalyst and the protein of interest (Figure 6)4. 
 
 
Figure 6: Proposed advantage of having two thiols in each active site of PDI, the escape 
mechanism4 
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In 2012 the Lees group published a paper detailing the synthesis of aromatic dithiols that 
were used as potential redox buffers for the folding of inclusion bodies (protein 
aggregates) into the native functional form of the protein disulfide5. The aromatic dithiols 
significantly increased the folding rate and also the yield of functional protein compared 
to aliphatic monothiols, aliphatic dithiols and even aromatic monothiols5. The Lees group 
has also recently proposed that aromatic thiols with an elongated alkyl group on the 
aromatic ring are expected to increase interactions with the hydrophobic core of disulfide 
containing proteins during folding, allowing easier access to buried disulfide bonds18.  
Insulin 
Overview 
Insulin is a hormone that plays an important role in the regulation of vertebrate 
metabolism19. It is also the most important pharmaceutical peptide for the treatment of 
diabetes20. This project uses insulin as a model protein disulfide because it contains three 
disulfide bonds that can break apart during thiol-disulfide exchange reactions, forming a 
suspension of α- and β-chain particles1,21, which scatters 650 nm light22 therefore making 
it convenient to monitor the reaction using UV-Vis spectroscopy. It has been shown that 
these unfolded chains expose their hydrophobic surfaces and bind together through 
hydrophobic interactions, eventually forming large, insoluble aggregates20. The 
wavelength of 650 nm was picked specifically because it shows a linear relationship 
between S-S bond reduction and precipitation22. Insulin contains 1 intra-chain disulfide 
bond on the α-chain (A6-A11) and 2 inter-chain disulfide bonds (A20-B19, A7-B7) that 
hold the α and the β chains together (Figure 7). It was found by Holmgren that the rate of 
precipitation of the insulin chains was much higher at pH 6.5 than at pH 8.022. This is 
consistent with the fact that insulin is less soluble at lower pH.  
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Figure 7: Structure of insulin, showing the α-chain (blue), β-chain (green) and the Cys-
Cys disulfide bonds (pink). Picture constructed using Chimera viewing software (PDB 
file: 6QQ7, bovine insulin). 
 
Typically, disulfide bonds are formed by the oxidation of cysteine residues and provide 
stability to the protein by minimizing the entropy of the unfolded state as they crosslink 
one part of the protein with another4. This oxidative protein folding mechanism mainly 
occurs inside the endoplasmic reticulum of eukaryotes4. All three disulfide bonds are 
essential for the receptor binding activity of insulin but contribute differently to the 
overall structure23. Deletion of the second interchain disulfide bond (A20-B19) has the 
most substantial influence on the structure as indicated by the loss of ordered secondary 
structure, increased susceptibility to proteolysis, and greatly reduced compactness23. This 
is most likely due to the fact that this bridge packs within itself a cluster of conserved 
aliphatic and aromatic side chains in the hydrophobic core19. The deletion of the 
intrachain disulfide bond causes the least change in the structure23. It is also known that 
the disulfide bonds are formed sequentially in the order A20-B19, A7-B7 and A6-A11 in 
the folding pathway of proinsulin (where A and B are the α and β chains and the number 
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designates placement of connecting amino acid in the amino acid sequence of insulin) 
(Figure 8).19,23 
 
 
Figure 8: Bovine insulin amino acid sequence, with disulfide bonds indicated as a solid 
line24 
 
 
These disulfide bonds are formed when proinsulin, the precursor to insulin, is folded in 
the endoplasmic reticulum prior to packaging into secretory granules in pancreatic β-cells 
which already contain the requisite processing enzymes23,25. The adult hormone is stored 
as Zn2+ stabilized hexamers (Figure 10) within these granules19. The hexamers precipitate 
in the granules, which increases the stability of mature insulin, making it inaccessible to 
proteases26. The hexamers dissociate upon secretion into the portal circulation, since only 
the monomeric form of insulin is able to bind its receptors in the liver and adipose 
tissue19,26. The zinc-mediated assembly may represent a defense against toxic misfolding 
in the secretory granule (Figure 9)19.  
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Figure 9: β-cell biosynthetic pathway for the packaging of insulin19. 
 
 
Figure 10: View of insulin dimer coordinated by histidine residues to 2 Zn2+ atoms (grey 
spheres). By combining with two other dimers, insulin forms a zinc-stabilized hexamer. 
The hexamer also contains a Ca2+ cation for increased stability. Picture constructed using 
Chimera viewing software (PDB file: 2ins). 
 
The disulfide bonds that hold the two chains of insulin together are post translational 
modifications involved in stabilizing the native structure27. Research has shown that it is 
not only the interchain disulfide bonds that are broken in a reduction reaction of insulin, 
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but when treated with thioglycolate solutions at pH 5, the major reaction that occurs is the 
cleavage of the intrachain disulfide bond on the α-chain21. It is not clear which of the 
three total disulfide bonds in the structure are more accessible to reagents and is therefore 
the likely candidate to be reduced first, although some researchers suppose that the 
intrachain disulfide bond will be reduced first21. Other researchers have pointed out that 
the rate of electrolytic reduction of the two interchain bonds was found to be significantly 
faster than that of the intrachain disulfide bond28. It seems that the likelihood of being 
reduced first depends on the experimental conditions and reagents used.  
In terms of accessibility, it seems like the A7-B7 inter disulfide bond is most accessible 
(exposed) based on a ball and stick model in Figure 11 (right). Additionally, because the 
hydrophobicity surface is pointed out (remember that B7 is surrounded by leucine and 
glycine, which are both hydrophobic) the molecule will want to expose the hydrophilic 
cysteine in the same way a micelle will want to fold the hydrophobic tails in a lipid 
bilayer inside itself while exposing the hydrophilic heads. On the other hand, the A20-
B19 and A6-A11 disulfide bonds have hydrophobicity pockets, which might be big 
enough to fit a gold thiolate molecule inside but are not quite as accessible.  
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Figure 11: Hydrophobicity surface of insulin, where the color gradient is determined by 
the Kyte-Doolittle scale, where blue is hydrophilic, red is hydrophobic and white is in 
between. Picture at right shows the cysteine residue hydrophobicity surface removed. 
Picture constructed using Chimera viewing software (PDB file: 6QQ7, bovine insulin). 
 
Each amino acid residue has an alpha carbon and two Ramachandran angles: ψ-psi and φ-
phi, the only two bonds that are available to freely rotate in the backbone, and therefore 
define the conformation of the protein. ψ is the angle between Cα and the carbonyl carbon 
(Figures 12 and 13), while φ is the angle between Cα and the amide that joins two 
residues together (Figures 14 and 15). The Ramachandran plot can be seen in Figure 16. 
Ψ and φ are limited by steric hinderance, as no two atoms may occupy the same space, 
and these regions of the Ramachandran plot will therefore be empty of any residues. 
These regions are not allowed by sterics. 
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Figure 12: Rotation of psi bond29 
 
 
Figure 13: Rotation of psi bond looking down the alpha carbon with the carbonyl carbon 
at the back29 
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Figure 14: Rotation of phi bond29 
 
Figure 15: Rotation of phi bond looking down the amide nitrogen with the alpha carbon 
at the back29 
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Figure 16: Ramachandran plot for bovine insulin. Cysteine residues colored red, all other 
residues blue. Green lines show the probability contour based on a reference set of high-
resolution proteins. Graph constructed using Chimera viewing software, picking general 
amino acid as the probability contour (PDB file: 6QQ7, bovine insulin).  
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As can be seen in the Ramachandran plot above, the top three cysteine residues (A11, 
A20 and B7) are most likely parts of loops or turns, the less ordered tertiary structures of 
proteins, although the general region where they are located (high psi, negative phi) 
usually codes for β-sheet as the most likely structure. The bottom three cysteine residues 
(A6, B19 and A7) are parts of α-helices. The Ramachandran plot further supports the 
structure above as the more likely structure of insulin and shows that in each disulfide 
bond of insulin, one of the cysteines is in a turn or loop, while the other is in an α-helix, 
making it difficult to judge the accessibility of one disulfide bond over another. However, 
it is possible to deduce something from the energetically unallowable regions of the 
Ramachandran plot. One of such unallowable regions spans the horizontal line where ψ is 
between -20° and 20° 29. This is the clash between an amide nitrogen and the hydrogen 
attached to another amide nitrogen. In comparison to the other steric clashes, this one is 
not as energetically unfavorable, yet it still provides some hinderance. The two top 
cysteine residues of the α-helix group in the Ramachandran plot are inside that region of 
N-H steric hinderance, while the bottom residue (A7) is not. This seems to propose that 
the A7 residue would be more stable and therefore unlikely to relieve any steric 
hinderance, supporting the notion that it would be the least likely to react with any gold 
thiolate compound. But that is only half of the disulfide bond, since gold cannot attack 
both sulfurs at the same time and will favor one over the other. The sulfur attacked might 
be chosen based on the possibility of alleviation of steric hinderance, which would make 
the A7 residue less likely to be attacked.  
Combined with the observation that A7-B7 is the most exposed disulfide bond according 
to hydrophobicity considerations, the prediction that A7 is less likely to be attacked 
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suggests that it might be possible to reason about the accessibility of the disulfide bonds 
as well as the likelihood that they will be reduced. However, any sort of conclusion is 
beyond the scope of this discussion. 
The Lees group has recently proposed that aromatic thiols with an elongated alkyl group 
on the aromatic ring are expected to increase interactions with the hydrophobic core of 
disulfide containing proteins during folding, allowing easier access to buried disulfide 
bonds18. This could be an advantage for the insulin disulfide bonds that are not as 
accessible as A7-B7. 
Reaction Between Insulin and Dithiothreitol 
From the DeCollo and Lees study it appears that they use DTT as a way to shift the 
equilibrium of the reaction toward reduced insulin1. DTT does this by reducing the 
aromatic disulfides formed in the interaction between insulin and an aromatic thiol back 
to the starting reactants. The reaction between insulin and an aromatic thiol can be seen in 
Figure 17 below. After the thiol reduces insulin, it forms a disulfide which, in the 
presence of DTT, is subsequently broken to react again with insulin. Thus, DTT is 
shifting the equilibrium of the reaction toward reduced insulin.  
 
 
Figure 17: Reduction of insulin by aromatic thiol in the absence of DTT1 
 
It is known that DTT significantly alters portions of secondary structural elements of 
insulin through aggregation, decreasing α-helical content from 34.8% to 13.2%, 
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increasing β-sheet content from 16.3% to 26.9% and random coil content from 32.3% to 
42.6%20.  
In comparison to PDI, 5 to 10 times the weight of an aromatic thiol is needed to match 
the rate of the reduction of insulin in the presence of DTT1. However, PDI, the in vivo 
catalyst, is expensive and can be difficult to separate from other proteins, thus leaving 
potential for aromatic thiols to catalyze the reaction more cheaply and just as effectively1. 
It is also a possibility to use PDI and aromatic thiols congruently12. 
Arguably, DTT can also be used to reduce insulin directly, as shown by Holmgren, 
during which reaction DTT forms a disulfide (Figure 18). In this reaction, thioredoxin 
acts as the redox buffer; however, DTT reduces insulin even without a redox buffer at the 
expense of a reduced reduction rate. 
 
Figure 18: Formation of DTT disulfide as a result of thioredoxin catalysis22 
 
An interesting application of the interactions between DTT and insulin is the percent of 
insulin binding to tissues that have been treated with DTT. Komori et al. showed that 
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binding of 125I-labeled insulin to rat liver membranes increased by 21.3% after the tissues 
have been treated with 0.5 mM DTT30. Furthermore, in rat adipocyte membranes, insulin 
binding was increased by 107.2% when the tissues had been treated with 1.0 mM DTT30. 
Both of these experiments showed elevated receptor affinity30. However, in rat and 
human erythrocyte membranes, DTT decreased binding in a dose-dependent manner, 
showing a decrease in receptor affinity30. This has interesting implications for molecules 
with similar biological activities when in contact with insulin to possibly have the same 
effect. The importance of insulin binding activity when exposed to DTT lies in that the 
major event of the insulin mechanism in the body is binding to insulin receptors in 
tissues. If DTT is impacting the rate of binding, this change might be attributed to the 
aggregation of insulin by DTT. 
Thiol-Disulfide Exchange 
Overview 
Thiol-disulfide exchange is an SN2 reaction31. It is bimolecular and the rate of reaction is 
dependent on both reactants31. The first step of the reaction is a deprotonation of thiol, 
while the second step is the SN2 attack of thiolate on disulfide31. The reaction proceeds 
through a transition state with a linear orientation of the three sulfur atoms31. A general 
schematic of a thiol disulfide exchange can be seen in Figure 19.  
 
(1) HSR	⇌ -SR + H+ 
(2) -SR +R’SSR’⇌ -SR’ +RSSR’ 
Figure 19: Generic thiol-disulfide mechanism 
 
 
Thiol-disulfide exchange is essential in structural and functional modifications that occur 
in many proteins31. The formation of mixed disulfides between glutathione or cysteine 
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and proteins is thought to play a role in cell signaling and regulatory pathways that are 
important in oxidative stress, apoptosis and aging31.  
 
Protein-Folding Thiol-Disulfide Exchange Reactions 
When proteins are overexpressed in bacteria, they are isolated as aggregates of inactive 
protein known as inclusion bodies, and to obtain the active form of the protein, the 
inactive protein is denatured and then folded in vitro1. The folding of disulfide containing 
proteins from denatured protein to native protein involves numerous thiol-disulfide 
interchange reactions1. A number of these reactions include a redox buffer, which is a 
mixture of a thiol (RSH) and the corresponding disulfide (RSSR)1. A study conducted in 
2001 by Todd DeCollo and Watson Lees concluded that aromatic thiols speed up the 
thiol disulfide exchange reaction between dithiothreitol (DTT) and insulin, as seen in 
Figure 201. The proposed reason for the higher catalytic activity of the aromatic thiols is 
the similarity of their pKa to that of the in vivo catalyst, protein disulfide isomerase 
(PDI), with lower pKa values correlating to a higher increase in protein folding and 
unfolding rates1. It is also known that aromatic thiolates (pKa=5~6) are better leaving 
groups than aliphatic thiolates such as glutathione (pKa=8.7), due to their lower thiol pKa 
values13. Additionally, aromatic thiolates are better nucleophiles than aliphatic thiolates 
with similar thiol pKa values13.  
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Figure 20: Reduction of native insulin by aromatic thiol and DTT at pH 6.51 
 
 
Using an aromatic thiol, the rate would be expected to not only increase when folding the 
protein, but in the reverse reaction as well. There are many factors that become important 
when studying protein folding. In many cases when proteins are overexpressed in 
bacteria, they are isolated as aggregates of inactive protein known as inclusion bodies1. 
To obtain the active version of the protein, the inactive protein is denatured and then 
folded1. For proteins containing disulfide bonds (such as insulin) the folding rate is 
usually limited by a thiol-disulfide interchange reaction. This reaction occurs in the 
protein itself as well as between the protein and the redox buffer, mentioned earlier1. The 
reaction occurs in the protein by breaking or forming the two disulfide bonds that hold 
the two peptide chains of insulin together, and it occurs between the protein and the redox 
buffer by breaking the disulfide bond on the outside of the alpha chain and also probably 
interacting with the newly formed thiolates on the inside of the two chains, as seen in 
Figure 21. The standard redox buffers, until the DeCollo/Lees study, were 
mercaptoethanol and cysteine derivatives such as glutathione1. As a precursor to the 
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study, DeCollo and Lees sought to design small molecule thiols as redox buffers for 
protein folding, basing their predictions on thiol pKa values and inherent nucleophilicity 
of PDI1.  During their study, they found that, as stated above, aromatic thiols significantly 
increased the rate of reaction between DTT and insulin1. They also found that the two-
step reduction of protein disulfides to dithiols is an important component of the folding 
process as it removes intermediates with mismatched disulfide bonds, as seen in Figure 
211. 
 
 
 
Figure 21: Folding of a protein with mismatched disulfide bonds1 
 
As can be seen in the figure, instead of holding the two chains of the protein together, the 
mismatched disulfide bonds prevent the protein from being effective, which is 
problematic, since only correctly folded proteins are functional. The refolding process 
gains native protein, which is fully functional. Since disulfide bonds are the only covalent 
bonds formed during in vitro folding, their formation is usually the rate-determining 
step32. A number of factors affect the folding rate of a disulfide containing protein with 
an aromatic thiol, namely the concentration of thiol in the neutral RSH form, the 
concentration of the thiolate anion and the reactivity of the thiolate anion13. The 
concentration of thiol in the thiolate form is important because thiolate is the reactive 
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species in the thiolate-disulfide interchange reaction13. As stated above, the reactivity of 
the thiolate is linked to the thiolate pKa: the lower the aromatic thiolate pKa, the higher 
the reactivity of the thiolate, although compared to aliphatic thiols with the same pKa, the 
aromatic thiols are more reactive13. In short, the thiol must have a small pKa (be 
relatively acidic). 
 
A mechanism for the refolding of insulin that was proposed by Gabor Markus predicts 
that the chance establishment of the first correct disulfide bond will greatly increase the 
chances of the formation of the next correct bond, by a) reducing the degrees of freedom 
available for random recombination, and by b) helping to align properly one or more 
additional pairs of correct sulfhydryl partners28. However, as insulin may interact not 
only with the reducing DTT but also with the RSH/RSSR buffer, the following eight 
reactions may be occurring during the in vitro folding of a protein disulfide32 (Figure 22). 
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Figure 22: Eight variations of the thiol-disulfide reaction that can occur during in vitro 
folding of a protein disulfide with a small molecule thiol (RSH) and a small molecule 
disulfide (RSSR)32 
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The first four of the reactions involve the protein thiolate acting as the nucleophile, while 
the last four reactions have the small molecule thiolate (DTT and/or aromatic thiol and/or 
gold thiolate) acting as the nucleophile32. 
Optimized Conditions for Protein Folding 
As found by the Lees research group, the yields of protein folding decrease with 
increasing protein concentration, so naturally, folding at low protein concentrations is 
advantageous5. However large amounts of refolding solution are needed to refold the 
protein, making it impractical on the large scale5. As an efficient strategy, the addition of 
folding aids was utilized (usually guanidine hydrochloride, urea, arginine, and glycerol)5. 
The proposed method that folding aids utilize for increasing the folding yield is by 
interfering with the intermolecular hydrophobic interactions that lead to protein 
aggregation during in vitro folding5. While aggregation causes reduced overall yields, 
folding aids are a way to increase yield, but folding aids generally decrease the rate of 
protein folding5. This is where aromatic dithiols were utilized. Aromatic dithiols were 
observed to increase both the rate of folding and overall yield, which has not been 
achieved by any other type of molecule so far5. Aromatic thiols are also much more cost 
effective compared to glutathione and PDI (aromatic thiols are about 1% the cost of 
glutathione)33. 
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Effect of Disulfide Bond Cleavage on Biological Activity 
Studies have shown that disulfide cleavage affects biological activity very drastically23. 
The half-maximal inhibition concentration for human insulin was found to be 0.71 nM 
(100%), while insulin mutants that had a deleted disulfide bond only had 0.2% of this 
activity, with some having a percentage that is even 4 to 5 times smaller than that23. 
Furthermore, the deletion of the disulfide bonds has an effect on the secondary structure 
of insulin23. Insulin contains approximately 45% α-helical content, whereas mutants with 
a deleted disulfide bond had anywhere from 11 to 22% α-helical content, and one had no 
α-helical content at all23.  
 
Gold Thiolate, Disulfide Exchange 
Overview 
The influence of gold(I) on the mechanism of thiolate, disulfide exchange was studied 
thoroughly over the past several years. It was found that gold(I) can indeed participate in 
thiolate-disulfide exchange due to several factors, such as gold(I)’s high affinity for 
sulfur and selenium31. Cellular targets for gold compounds primarily include cysteine 
and/or selenocysteine-containing proteins31. In addition, early studies have shown that 
gold accumulates in inflamed synovial tissues, and similarly to other heavy metals, Au(I) 
ions lead to expression of thionein31. This and other evidence cited above suggests that 
the gold thiolate-disulfide exchange mechanism is important and warrants further study.  
 
The rate law for a gold thiolate-disulfide exchange reaction is overall second order, first 
order in gold(I)-thiolate and disulfide31. Electrochemical/chemical research is consistent 
with a mechanism involving the formation of a [Au-S,S-S], four-centered metallacycle 
intermediate during the exchange (Figure 23)31.  
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Figure 23: Four-centered metallacycle intermediate 
 
Gold Thiolate, Disulfide Exchange Mechanism 
In general, a proposed gold thiolate-disulfide exchange between insulin and either 
Et3PAuSpy or Et3PAuSba can be seen in Figure 24 below where the first reactant is the 
gold thiolate complex, the second reactant is insulin, the first product is an assumed gold 
thiolate-insulin complex, and the other product is a mixed disulfide formed from the 
thiolate ligand and the other part of the insulin that is not involved in the gold complex. 
 
Et3PAu-SR + R’SSR’’ → Et3PAu-SR’ + RSSR’’ 
 
Figure 24: Predicted gold thiolate-disulfide exchange with an unsymmetrical disulfide 
 
 
However, research has shown that gold-thiolates undergo exchange in a two-step manner, 
first forming an unsymmetrical disulfide and then reacting this disulfide again to produce 
a symmetric disulfide (Figure 25)8,34.  
 
 
 
Figure 25: Two-step reaction of gold-thiolate with symmetric disulfide34. 
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Gold Thiolates as Disulfide Bond Cleavage Reagents 
According to recent gas phase research, the high affinity of gold to sulfur suggests gold(I) 
complexes may prove useful as disulfide cleavage reagents35. Possible sites of cleavage 
are seen in Figure 26. It was found that disulfide bond (Figure 26 bond 1) cleavage 
becomes less favorable as the size of the peptide increases35. The fragmentation is instead 
dominated by amide bond (Figure 26 bonds 3 and 4) cleavage via elimination of 
CH2NH2, and no disulfide bond cleavage is observed36. This is because in comparison to 
the energetics of simple amide bond cleavage, S-S bond cleavage reactions are higher in 
energy24,36. However, out of all coinage metal systems studied, Me3PAu+ was superior in 
promoting disulfide bond cleavage (60% S-S bond cleavage, where the second highest 
was Ag with 10.8% S-S bond cleavage)35.  
 
Figure 26: Possible bond cleavages in a disulfide bond between two cysteine residues35 
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A proposed electrophilic mechanism that was based on potential high S affinities and 
previous studies was proposed by the Lioe research group (Figure 27). In the case of 
insulin, one chain would form product A, while the other chain would form the cyclic 
byproduct, where the β-chain is expected to contain a five-membered ring at each 
cysteine location with the sulfur of the cysteine bound to the C-terminal amide nitrogen. 
This is supported by further studies27. It is worthwhile to point out that this mechanism is 
based on ionic versions of the metal complex and insulin and is also based on the method 
of low-energy collision-induced dissociation (CID) reactions, which provide structural 
information on peptides containing a disulfide bond37. 
 
Figure 27: Proposed electrophilic neighboring group mechanism for the cleavage of 
disulfide bonds upon the coordination of a metal complex to one of the sulfurs of the 
disulfide bond. X and Y are nearby amino acids35. 
 
Proteins as a Mode of Transport for Gold Thiolate Compounds 
It is known that upon entering the body, Au(I) becomes bonded to cysteine sites in 
glutathione, blood proteins and enzymes and is extensively distributed around the body 
while undergoing rapid ligand displacement reactions8,38. It is known that most of the 
circulating Au from antiarthritic drugs is bound to the cysteine-34 of serum albumin 
(pKa~5) and transcription factors (Jun, Fos, NF-kB), which have cysteine residues 
flanked by basic lysine and arginine residues2. Albumin can transfer Au(I) into cells via a 
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thiol shuttle mechanism7. When a phosphine gold ligand binds to Cys-34 of albumin, it 
flips the cysteine residue from the buried pocket of albumin to the surface, where it is 
more readily accessible (Figure 28)39. 
 
 
Figure 28: Structural transition induced by Au(I) in serum albumin39. 
 
 
Since most gold drugs release the Et3PAu+ moiety in vivo, the other attachment in the 
complex could potentially regulate the permeability into the cell and the ease of transport.  
 
Gold Thiolate as Redox Buffer 
If the formation of the DTT disulfide in this reaction is possible, then it is also possible 
that an aromatic thiol or a gold thiolate could interact with DTT in the same way that 
DTT interacts with aromatic thiols, namely a gold thiolate could be used to reduce the 
DTT disulfide and shift the equilibrium of the reaction toward reduced disulfide. 
However, phosphine gold(I) thiolate complexes have been shown to react with aromatic 
disulfides via two pathways: 1) thiolate-disulfide exchange and 2) pathway that leads to 
the formation of phosphine oxide34. These pathways are in competition. If gold thiolates 
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are reacting with aromatic disulfides, it could be possible that they may be reacting with 
DTT disulfides after DTT reduces insulin.  
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METHODS 
	
Materials 
Insulin (bovine, ≥ 25 USP units/mg (HPLC), powder) and K2HPO4 were acquired from 
Alfa Aesar. Dithiothreitol (DTT) was acquired from Fluka BioChemika and Acros 
Organics. Et3PAuCl, Trizma, d-Chloroform, DMSO, 4-mercaptobenzoic acid and 2-
mercaptopyridine were acquired from Sigma-Aldrich. EDTA, KH2PO4, HCl, and NaOH 
were acquired from Fischer Scientific. Ethanol was acquired from Pharmco-Aaper. 
Et3PAuSpy and Et3PAuSba were both synthesized in lab.  
Preparation of insulin stock solution # 122 
To prepare a 10 mg/mL insulin stock solution, 0.0250 g of bovine insulin was dissolved 
in 4 mL of 0.05 M Tris-Cl buffer, pH 8.00, and adjusted to pH 2 by the addition of 1 M 
HCl and rapidly titrated back to pH 8 with 1 M NaOH (about 4 drops each of HCl and 
NaOH). The solution was then adjusted to 5 mL total volume with distilled water. The 
stock solution was stored at freezing temperature. 
Preparation of insulin stock solution # 21 
To prepare a 0.167 mM insulin stock solution, 1 mL of a 10 mg/mL solution of insulin 
(stock solution 1) was diluted to 8 ml with 0.1 M phosphate buffer. This cloudy solution 
was made clear by adjusting to pH 3 by adding 1 M HCl dropwise and then rapidly 
adjusting to pH 8 by adding 1 M NaOH dropwise. The final volume of insulin was 
adjusted to 10 mL with distilled water. The stock solution was stored at freezing 
temperature. 
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RESULTS AND DISCUSSION 
	
Each experiment contains a Methods section and a Results and Discussion section. It 
seems more convenient to use this method of organization so that the reader can refer to 
the components of the reaction vessel when reading the results and discussion.  
Table 1: List of experiments, reactants and final concentrations in cuvette (mM). All 
experiments conducted in a buffer were at pH 6.5 (buffer pH). Insulin’s pH is 8.  
Experiment Name Reactants Final Concentration 
in Cuvette (mM) 
A 4-mercaptobenzoic acid, DTT, 
insulin 
0.266, 0.333, 0.0556 
B DTT, insulin 0.333, 0.0556 
C  4-mercaptobenzoic acid, 
insulin 
0.266, 0.0556 
D 2-mercaptopyridine, DTT, 
insulin 
0.266, 0.333, 0.0556 
E Et3PAuSpy, DTT, insulin 0.266, 0.333, 0.0556 
F Et3PAuSpy, insulin 0.266, 0.0556 
G Et3PAuSpy, DTT varied (titration) 
H Et3PAuCl, insulin 0.266, 0.0556 
I Et3PAuCl, DTT 0.266, 0.333 
 
Experiment A (4-mercaptobenzoic acid, DTT and insulin) 
Methods: To prepare 20 mL of a 5.0 mM 4-mercaptobenzoic acid solution, 0.0154 g 
(0.0999 mmol) were dissolved in 20 mL of phosphate buffer. The solution was stirred 
and heated until all of the solid was dissolved in the solution. To prepare 20 mL of a 25.0 
mM dithiothreitol solution, 0.0778 g (0.504 mmol) were dissolved in 20 mL of phosphate 
buffer. The solution was stirred until all of the solid was dissolved in the solution. Insulin 
stock solution 2 was warmed to room temperature. The UV-Vis was autozeroed on 
phosphate buffer, not air. To make the cuvette solution, 1 mL of insulin stock solution 2 
was added to the cuvette, followed by 1.8 mL of phosphate buffer, 160.0 µL of 4-
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mercaptobenzoic acid solution and 40.0 µL of dithiothreitol solution. The UV-Vis was set 
up to scan the cuvette every 3 minutes (including the 25 sec it takes to actually perform a 
scan) in the wavelength range of 300-800 nm. The total number of scans was 283 
(approx. 14 hrs). The absorbance at 650 nm as a function of time in minutes was plotted 
in Figure 29. 
 
Figure 29: Absorbance at 650 nm plotted as a function of time of the reaction between 4-
mercaptobenzoic acid, DTT and insulin. Graph shows the formation of a colloidal 
suspension of the α and β chains precipitating out of solution. The plot shows a lag time, 
during which the particles are predicted to be reaching a critical concentration and start 
aggregating after reaching it (200 min). Upon reaching the maximum size of the 
aggregate, the particles start falling out of solution, becoming too dense to form a 
colloidal suspension. This is evidenced by the decrease in light scatter at 820 min.  
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Results and Discussion: This experiment was carried out as a proof of concept of the 
procedure for a thiol-mediated DTT reduction of insulin described by DeCollo and Lees1. 
Because of a different total volume of this reaction from theirs (their total volume was 1.2 
mL, while the total volume of the experiments in this study was 3 mL), the 
concentrations of the reactants in this experiment differed from theirs, although the molar 
ratio was the same. In terms of a proof of concept, the reaction was a success, since there 
was a colloidal suspension forming in the cuvette with time, increasing the light scatter 
until the particles become too dense for the solution and begin falling. As reported by 
Holmgren, there is a considerable lag time that occurs before the precipitation of the 
chains in solution22, in this case, approximately 3 hours. A proposed mechanism for the 
reaction between 4-mercaptobenzoic acid, insulin and DTT can be seen in Figure 30. 
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Figure 30: Proposed mechanism for the reaction between 4-mercaptobenzoic acid, insulin 
and DTT, where R1 and R2 are the α and β chains of insulin. DTT acts as a redox buffer, 
breaking the aromatic disulfide to provide more 4-mercaptobenzoic acid to reduce 
insulin, thereby shifting the equilibrium of the reaction toward reduced insulin. 4-
mercaptobenzoic acid also acts as a redox buffer. 
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Experiment B (DTT and insulin) 
Methods: To prepare 20 mL of a 25.0 mM dithiothreitol solution, 0.0777 g (0.504 mmol) 
were dissolved in 20 mL of phosphate buffer. The solution was stirred until all of the 
solid was dissolved in the solution. Insulin stock solution 2 was warmed to room 
temperature. The UV-Vis was autozeroed on phosphate buffer, not air. To make the 
cuvette solution, 1 mL of insulin stock solution 2 was added to the cuvette, followed by 
1.96 mL of phosphate buffer and 40.0 µL of dithiothreitol solution. The UV-Vis was set 
up to scan the cuvette every 3 minutes (including the 25 sec it takes to actually perform a 
scan) in the wavelength range of 300-800 nm. The total number of scans was 502 
(approx. 25 hrs). The absorbance at 650 nm as a function of time in minutes was plotted 
in Figure 31. 
 
Figure 31: Absorbance at 650 nm plotted as a function of time of the reaction between 
DTT and insulin. 
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Results and Discussion: This experiment was also done as a second proof of concept, as 
DeCollo and Lees had carried out the reaction between DTT and insulin in order to 
compare this reaction to the reaction of DTT and insulin in the presence of an aromatic 
thiol in terms of relative rates. The comparison between Experiments A and B can be 
seen in Figure 33 and the relative rates can be seen as the slope of the linear fit on the 
linear segment of both curves in Figure 34. The relative rate of experiment A is roughly 
1.7 times that of experiment B, consistent with the results found by DeCollo and Lees, 
that aromatic thiols increase the rate of the reduction of insulin by DTT. Lees reported a 
relative rate of 1.6 between the reaction of 4-mercaptobenzoic acid, insulin and DTT 
relative to insulin and DTT only1. A proposed mechanism for the reaction between DTT 
and insulin can be seen in Figure 32. 
 
 
 
Figure 32: Proposed mechanism for the reaction between insulin and DTT, where R1 and 
R2 are the α and β chains of insulin. 
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Figure 33: Comparison between Experiment A (4-mercaptobenzoic acid, DTT and 
insulin) and Experiment B (DTT and insulin) 
 
 
Figure 34: Comparison of the relative rates of Experiments A (4-mercaptobenzoic acid, 
DTT and insulin) and B (DTT and insulin), where the linear range for Experiment A is 
300-500 min and the linear range for experiment B is 400-580 min. 
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Experiment C (4-mercaptobenzoic acid and insulin) 
Methods: To prepare 20 mL of a 5.0 mM 4-mercaptobenzoic acid solution, 0.0154 g 
(0.0999 mmol) were dissolved in 20 mL of phosphate buffer. The solution was stirred 
and heated until all of the solid was dissolved in the solution. Insulin stock solution 2 was 
warmed to room temperature. The UV-Vis was autozeroed on phosphate buffer, not air. 
To make the cuvette solution, 1 mL of insulin stock solution 1 was added to the cuvette, 
followed by 1.86 mL of phosphate buffer and 160.0 µL of 4-mercaptobenzoic acid 
solution. The UV-Vis was set up to scan the cuvette every 3 minutes (including the 25 
sec it takes to actually perform a scan) in the wavelength range of 300-800 nm. The total 
number of scans was 483 (approx. 24 hrs).  
Results and Discussion: This reaction was carried out over the course of 24 hours and 
showed no result in the form of an increase in light scatter, suggesting either that there is 
no reaction between 4-mercaptobenzoic acid and insulin or that it has a significantly 
reduced rate and therefore has a considerably long lag time. Lees does not report the 
relative rates of this experiment to others. 
Changing the Thiol 
During synthesis of the proposed Et3PAuSba compound, to be used in later studies, it was 
found that the compound is not soluble in phosphate buffer. This undermines the 
experiment as the compound will precipitate out of solution when put in the cuvette for a 
reaction. Instead, it was proposed to switch the thiol from 4-mercaptobenzoic acid to 2-
mercaptopyridine, since Et3PAuSpy was known to be at least partially soluble in 
phosphate buffer.  
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Experiment D (2-mercaptopyridine, DTT and insulin) 
Methods: To prepare 20 mL of a 5 mM solution of 2-mercaptopyridine, 0.0216 g (0.194 
mmol) were dissolved in 20 mL of buffer. The solution was stirred until all of the solid 
was dissolved in the solution. To prepare 20 mL of a 25.0 mM dithiothreitol solution, 
0.0768 g (0.498 mmol) were dissolved in 20 mL of phosphate buffer. The solution was 
stirred until all of the solid was dissolved in the solution. Insulin stock solution 2 was 
warmed to room temperature. The UV-Vis was autozeroed on phosphate buffer, not air. 
To make the cuvette solution, 1 mL of insulin stock solution 2 was added to the cuvette, 
followed by 1.8 mL of phosphate buffer, 160.0 µL of 2-mercaptopyridine solution and 
40.0 µL of dithiothreitol solution. The UV-Vis was set up to scan the cuvette every 3 
minutes (including the 25 sec it takes to actually perform a scan) in the wavelength range 
of 300-800 nm. The total number of scans was 243 (approx. 12 hrs). The absorbance at 
650 nm as a function of time in minutes was plotted in Figure 35. 
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Figure 35: Absorbance at 650 nm plotted as a function of time of the reaction between 2-
mercaptopyridine, DTT and insulin. 
 
Results and Discussion: This reaction was compared to Experiment A, as the only change 
from Experiment A to D was the switch of the thiol used in the experiment. The 
comparison can be seen in Figure 36. The new thiol (2-mercaptopyridine) seems to be 
catalyzing the reduction of insulin by DTT in the same manner, and so is a viable 
substitute. The proposed mechanism for the reaction between 2-mercaptopyridine, DTT 
and insulin can be seen in Figure 37. The mechanism is based on the known mechanism 
for Experiment A, substituting the 4-mercaptobenzoic acid for 2-mercaptopyridine, 
which has been shown in Figure 36 to have the same effect on the reaction between 
insulin and DTT. 
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Figure 36: Comparison between Experiment A (4-mercaptobenzoic acid, DTT and 
insulin) and Experiment D (2-mercaptobenzoic acid, DTT and insulin). 
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Figure 37: Proposed mechanism between 2-mercaptopyridine, insulin and DTT, where R1 
and R2 are the α and β chains of insulin. DTT acts as a redox buffer, breaking the 
aromatic disulfide to provide more 2-mercaptopyridine to reduce insulin, thereby shifting 
the equilibrium of the reaction toward reduced insulin. The two thiols of DTT act as an 
oxidation-reduction couple, in the same way as PDI’s two active site cysteine residues act 
together40. 
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Experiment E (Et3PAuSpy, DTT and insulin) 
	
Methods: To prepare 1 mL of a 5.0 mM Et3PAuSpy solution, 0.0021 g (0.0049 mmol) 
were dissolved in 0.2 mL of dimethyl sulfoxide and diluted to 1 mL with phosphate 
buffer. The solution was stirred until all of the solid was dissolved in the solution. To 
prepare 20 mL of a 25.0 mM dithiothreitol solution, 0.0781 g (0.5063 mmol) were 
dissolved in 20 mL of phosphate buffer. The solution was stirred until all of the solid was 
dissolved in the solution. Insulin stock solution 2 was warmed to room temperature. The 
UV-Vis was autozeroed on phosphate buffer, not air. To make the cuvette solution, 1 mL 
of insulin stock solution 2 was added to the cuvette, followed by 1.8 mL of phosphate 
buffer, 160.0 µL of Et3PAuSpy solution and 40.0 µL of dithiothreitol solution. The UV-
Vis was set up to scan the cuvette every 3 minutes (including the 25 sec it takes to 
actually perform a scan) in the wavelength range of 300-800 nm. The total number of 
scans was 273 (approx. 14 hrs). The absorbance at 650 nm as a function of time in 
minutes was plotted in Figure 38.  
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Figure 38: Absorbance at 650 nm plotted as a function of time of the reaction between 
Et3PAuSpy, DTT and insulin. 
 
Results and Discussion: This experiment was carried out to see if replacing a thiol with a 
gold thiolate would have the same effect in terms of increasing the rate of the reaction 
between DTT and insulin. It appears that Et3PAuSpy increases the rate of the reaction 
between insulin and DTT more so than 2-pyridinethiol (Figure 40). In order to compare 
the effect Et3PAuSpy has on the reaction, the comparison between Experiment B and 
Experiment E needs to be made (Figure 41). As can be seen in this graph, Et3PAuSpy 
considerably reduces the lag time of the reaction, as well as noticeably increasing the 
rate.  
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Similar to how DTT shifted the equilibrium toward reduced insulin when an aromatic 
thiol was combined with insulin in the presence of DTT, it is possible that DTT has the 
same function in this experiment (see Figure 43).  
The offset in the two slopes in Figures 40 and 41 is most likely due to the possibility of 
two separate mechanisms that form different kinds of particles that aggregate at different 
rates. This supposition is based on the knowledge that Et3PAuSpy reacts with DTT to 
form 2-pyridinethiol (Experiment G) and the knowledge that Et3PAuSpy also reacts with 
insulin to form a colloidal suspension that scatters light at 650 nm (Experiment F). These 
results suggest an explanation for the initial increase in light scatter, followed by a lag 
time and then again an increase until reaching a maxima in the graph of Figure 38, which 
shows the reaction between Et3PAuSpy, DTT and insulin. 
 
Figure 40: Comparison between experiments D (2-pyridinethiol, DTT and insulin) and E 
(Et3PAuSpy, DTT and insulin) 
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Figure 41: Comparison between experiments B (DTT and insulin) and E (Et3PAuSpy, 
DTT and insulin) 
Experiment F (Et3PAuSpy and insulin) 
Methods: To prepare 1 mL of a 5.0 mM Et3PAuSpy solution, 0.0021 g (0.0049 mmol) 
were dissolved in 0.2 mL of dimethyl sulfoxide and diluted to 1 mL with phosphate 
buffer. The solution was stirred until all of the solid was dissolved in the solution. Insulin 
stock solution 2 was warmed to room temperature. The UV-Vis was autozeroed on 
phosphate buffer, not air. To make the cuvette solution, 1 mL of insulin stock solution 2 
was added to the cuvette, followed by 1.86 mL of phosphate buffer and 160.0 µL of 
Et3PAuSpy solution. The UV-Vis was set up to scan the cuvette every 3 minutes 
(including the 25 sec it takes to actually perform a scan) in the wavelength range of 300-
800 nm. The total number of scans was 241 (approx. 12 hrs). The absorbance at 650 nm 
as a function of time in minutes was plotted in Figure 42.  
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Figure 42: Absorbance at 650 nm plotted as a function of time of the reaction between 
Et3PAuSpy and insulin 
 
Results and Discussion: This experiment was carried out to control for DTT. If insulin 
reacts with Et3PAuSpy itself, without needing DTT as a reducing agent, then the 
mechanism of the reaction gets more complicated, proposing the idea that there is more 
than one reaction happening when Et3PAuSpy, DTT and insulin are mixed together. As 
can be seen in Figure 42, insulin does react with Et3PAuSpy, and at a noticeably faster 
rate than the other reactions that have been investigated in this study. In comparison to 
the reaction with DTT, the reaction without DTT is much faster (Figure 44). The 
proposed mechanism for this reaction can be seen in Figure 43. The mechanism is based 
on the knowledge that gold-sulfur compounds undergo thiolate-disulfide exchange by 
forming a metallacycle intermediate with a disulfide. The shape of the graphs in Figure 
0
0.02
0.04
0.06
0.08
0.1
0.12
0 100 200 300 400 500 600 700 800
Ab
so
rb
an
ce
	a
t	6
50
	n
m
Time	(min)
Et3PAuSpy	and	insulin
		 56 
44 is very different, with drastically different maxima, possibly indicating that the size of 
the particles grows more rapidly with gold. 
 
Figure 43: Proposed mechanism for the reaction between Et3PAuSpy and insulin, where 
R1 and R2 are the α and β chains of insulin. 
 
Figure 44: Comparison of experiments E (Et3PAuSpy, DTT and insulin) and F 
(Et3PAuSpy and insulin) 
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Experiment G (Et3PAuSpy and DTT) 
UV-Vis: 
Method: To prepare 10 mL of 3 mM solution of dithiothreitol, 0.0048 g (0.0311 mmol) 
were dissolved in 10 mL of ethanol. To make this solution more dilute for UV-Vis, 0.5 
mL of the 3 mM solution were diluted to a volume of 3 mL with ethanol. To prepare 3 
mL of a 1 mM solution of Et3PAuSpy, 0.0029 g (0.0068 mmol) were dissolved in 
ethanol. To make this solution more dilute for UV-Vis, 1 mL of the 1 mM solution was 
diluted to a volume of 14 mL with ethanol. The concentrations of Et3PAuSpy and 
dithiothreitol before titration were 0.1 mM and 0.5 mM respectively. About 2 mL of the 
0.5 mM solution of Et3PAuSpy was transferred to the cuvette and scanned (Et3PAuSpy in 
Figure 46). Then, the solution in the cuvette was titrated with the 0.1 mM solution of 
dithiothreitol by adding one drop at a time and scanning the solution, to create the graph 
in Figure 45. The range of UV-Vis was 200-500 nm. 
 
Figure 45: Absorbance plotted as a function of wavelength (nm) of Et3PAuSpy with 
DTT, added dropwise 
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Results and Discussion: Experiment G was carried out to look at the possible reaction 
between Et3PAuSpy and DTT. The UV-Vis data was acquired using a titration of 
Et3PAuSpy with DTT added dropwise to a solution of Et3PAuSpy over a period of 30 
minutes. Figure 45 shows the absorbance at 3, 6, 9 and 12 drops of DTT added to the 
cuvette. It can be observed from the graph that Et3PAuSpy is converted to 2-pyridinethiol 
in the reaction with DTT with three isosbestic points at approximately 227, 300 and 327 
nm. A comparison of the initial spectra of 2-pyridinethiol, DTT and Et3PAuSpy with the 
reaction solution of Et3PAuSpy and DTT is made in Figure 46. It is clear from just 
comparing the reaction solution with the spectrum of 2-pyridinethiol that it is a 
conversion of Et3PAuSpy to 2-pyridinethiol because of the way the peaks are lined up 
one on top of the other. The 1H NMR data also supports this conclusion (Figures 47-50). 
Table 2 (in conjunction with Figure 51) summarizes the 1H NMR data and gives a 
thorough comparison of the three spectra. It is clear that Et3PAuSpy is left over after the 
reaction is finished, due to the peaks associated with Et3PAuSpy still being present in the 
reaction spectrum (Figure 49). However, two new peaks have appeared in the reaction 
spectrum (Figure 49) that are not attributed to either DTT or Et3PAuSpy. These peaks (c 
and d as labeled on 2-pyridinethiol) are indications that 2-pyridinethiol has dissociated 
from the gold complex. 2-pyridinethiol should also theoretically have a peak at 8.62 ppm 
that integrates for the e proton, but it is not observed on the spectrum of 2-pyridinethiol, 
which might be a signal to noise ratio problem. There are a couple of impurities in the 
spectra and several water peaks, but those have been carefully specified in the table. The 
thiol peaks from 2-pyridinethiol are not observed in addition to the missing DTT OH 
group peaks, which is common for 1H NMR spectra. It is proposed from the data that 
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peak 6 for Et3PAuSpy is the combination of 2-pyridinethiol’s peaks 6 and 7 (the chemical 
shift due to gold’s electron-withdrawing character). It is also proposed that the reaction 
between Et3PAuSpy and DTT could form the disulfide pictured in Figure 53. However, 
this hypothesis can be rejected due to the following two reasons: 1) one of the 1H NMR 
peaks for the disulfide (Figure 52) at 8.5 ppm is not observed in the reaction spectrum 
and 2) while literature values for the UV absorbance for the disulfide show two peaks 
(238 and 282 nm) (31), the 238 nm peak is not observed in the reaction UV spectrum. 
Both of these reasons support the conclusion that the disulfide was not a product of the 
reaction between Et3PAuSpy and DTT. 
 
 
Figure 46: Comparison of 2-pyridinethiol, DTT, Et3PAuSpy and the reaction of DTT and 
Et3PAuSpy 
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1H NMR: 
This reaction was also investigated by 1H NMR, by first acquiring a 1H NMR scan of the 
reactants and then mixing them in a 1:1 volume equivalent and acquiring a scan of the 
solution in CDCl3 (Figures 47-50). 
 
 
Figure 47: 1H NMR spectrum of Et3PAuSpy in CDCl3 
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Figure 48: 1H NMR spectrum of DTT in CDCl3 
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Figure 49: 1H NMR spectrum of the reaction between DTT and Et3PAuSpy in CDCl3 
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Figure 50: 1H NMR spectrum of 2-pyridinethiol in CDCl3 
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Table 2: Location of peaks on 1H NMR spectrum and indicated protons 
 Et3PAuSpy DTT Et3PAuSpy + DTT 2-pyridinethiol 
Peak Location 
(ppm) 
Proton 
Designation 
Location 
(ppm) 
Proton 
Designation 
Location 
(ppm) 
Proton 
Designation 
Location 
(ppm) 
Proton 
Designation 
1 1.21 a,c,e 1.5 a,h 1.2 A,c,e 
(Et3PAuSpy) 
1.24 Impurity 
2 1.55 Water 2.6-2.75 b,g 1.57 Water 
(broad peak- 
not DTT) 
1.56 Water 
3 1.87 b,d,f 3.7 c,e 1.88 B,d,f 
(Et3PAuSpy) 
3.71 Impurity 
4 6.80 g 7.25 CDCl3 2.75 b,g (DTT) 6.74 b 
5 7.25 CDCl3 - - 3.75 c,e (DTT) 7.25 CDCl3 
6 7.45 i,h - - 6.8 g 
(Et3PAuSpy) 
7.37 c 
7 8.22 j - - 7.0 Impurity 7.56 d 
8 - - - - 7.2 Impurity 12.93 Impurity 
(OH) 
9 - - - - 7.25 CDCl3 - - 
10 - - - - 7.3 Impurity - - 
11 - - - - 7.37 c (2-pyr) - - 
12 - - - - 7.55 d (2-pyr) - - 
13 - - - - 8.2 j 
(Et3PAuSpy) 
- - 
 
 
 
Figure 51: Proton labeling from left to right: Et3PAuSpy, DTT and 2-pyridinethiol 
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Figure 52: 1H NMR spectrum of 2-pyridinethiol disulfide (SciFinder) 
 
 
 
Figure 53: Possible 2-pyridinethiol disulfide 
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Oxidized DTT 
DTT is unstable in its reduced form and its oxidation can be further catalyzed by metal 
ions41. A study in 2013 showed that the redox potential of the reaction changed by 3-5% 
during the 2.5 hrs needed for the reactions investigated41. Even though it has often been 
assumed that under anaerobic conditions and in the presence of a chelating agent such as 
EDTA the reaction should maintain a constant redox potential, the 2013 study proved this 
assumption false41. In general, this should not be an issue at small enough concentrations 
of DTT; however, the possibility of DTT oxidizing while sitting in solution for some time 
was tested by UV-Vis. The solution of DTT used for the titration was scanned initially 
and after 30 minutes. Unlike reduced DTT, which is not UV active, oxidized DTT is UV 
active with an absorbance peak at 283 nm (Figure 54)14. The scan of the DTT solution 
after sitting for 30 minutes showed no absorbance peak, therefore suggesting that DTT 
does not oxidize while sitting in solution for the amount of time required to do the 
titration of Et3PAuSpy with DTT (Figure 55). 
 
Figure 54: Molar absorbance of oxidized DTT as a function of wavelength. Solvent is 
0.05 M phosphate buffer, pH 814.  
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Figure 55: UV-Vis scan of the DTT solution right after it was made and after it has been 
sitting uncovered for 30 minutes (the time interval it took for the titration), showing no 
oxidizing activity, as DTTred is not UV-active, while DTTox is UV-active (peak at 282 
nm). 
 
Experiment H (Et3PAuCl and insulin) 
Methods: To prepare 3.7 mL of a 5.0 mM Et3PAuSpy solution, 0.0065 g (0.0185 mmol) 
were dissolved in phosphate buffer. The solution was stirred until all of the solid was 
dissolved in the solution. Insulin stock solution 2 was warmed to room temperature. The 
UV-Vis was autozeroed on phosphate buffer, not air. To make the cuvette solution, 1 mL 
of insulin stock solution 2 was added to the cuvette, followed by 1.86 mL of phosphate 
buffer and 160.0 µL of Et3PAuCl solution. The UV-Vis was set up to scan the cuvette 
every 3 minutes (including the 25 sec it takes to actually perform a scan) in the 
wavelength range of 300-800 nm. The total number of scans was 242 (approx. 12 hrs). 
The absorbance at 650 nm as a function of time in minutes was plotted in Figure 56. 
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Figure 56: Absorbance at 650 nm plotted as a function of time of the reaction between 
Et3PAuCl and insulin 
 
Results and Discussion: Experiment H was carried out to see how Et3PAuCl would react 
with insulin. According to the UV spectrum above, Et3PAuCl does react with insulin, but 
the four-centered metallacycle intermediate mechanism proposed for the reaction 
between Et3PAuSpy and insulin does not seem likely in this case, due to the nature of 
Et3PAuCl, which usually undergoes a ligand-substitution. However, the thiol-containing 
amino acid cysteine was found to react with bromo(triethylphosphine)gold in aqueous 
solution42. The product, 2-amino-2-carboxyethylthio(triethylphosphine)gold (Figure 57) 
was unstable and its aqueous solution slowly deposited an amorphous precipitate of 
aurous cysteinate42. A freshly made solution of the product was acidified with 
hydrochloric acid to give cysteine and chloro(triethylphosphine)gold42. This seems to 
suggest that Et3PAuCl can react with the cysteine residues of insulin in the same manner, 
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that is if the cysteines were free and were not part of disulfide bonds. It is possible that 
Et3PAuCl may be interacting with nearby amino acids that have donor atoms, such as 
histidine. However, a mechanism for this reaction cannot be gleaned at this point in the 
research. 
 
 
Figure 57: Structure of 2-amino-2-carboxyethylthio(triethylphosphine)gold 
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Experiment I (Et3PAuCl and DTT) 
UV-Vis: 
Methods: To prepare 10 mL of 3 mM solution of dithiothreitol, 0.0046 g (0.0298 mmol) 
were dissolved in 10 mL of ethanol. To make this solution more dilute for UV-Vis, 0.5 
mL of the 3 mM solution were diluted to a volume of 3 mL with ethanol. To prepare 10 
mL of a 1 mM solution of Et3PAuCl, 0.0035 g (0.0099 mmol) were dissolved in ethanol. 
To make this solution more dilute for UV-Vis, 1 mL of the 1 mM solution was diluted to 
a volume of 15 mL with ethanol. The final concentrations of Et3PAuCl and dithiothreitol 
were 0.1 mM and 0.5 mM respectively. About 2 mL of the 0.1 mM solution of Et3PAuCl 
was transferred to the cuvette and scanned, showing no peak, which was expected as 
Et3PAuCl is not UV active. Then, the solution in the cuvette was titrated with the 0.5 mM 
solution of dithiothreitol by adding one drop at a time and scanning the solution. The 
range of UV-Vis was 200-500 nm. There were no observable peaks as more DTT was 
added dropwise, suggesting that DTT does not react with Et3PAuCl.  
1H NMR: 
To confirm this hypothesis, the reaction was also investigated using 1H NMR, by first 
acquiring a 1H NMR scan of the reactants and then mixing them in a 1:1 volume 
equivalent and acquiring a scan of the solution in CDCl3 (Figures 59-61). Table 3 in 
conjunction with Figure 62 summarize the 1H NMR data and give a comparison between 
reactants and the reaction solution. 
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Figure 59: 1H NMR spectrum of Et3PAuCl in CDCl3 
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Figure 60: 1H NMR spectrum of DTT in CDCl3 
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Figure 61: 1H NMR spectrum of the reaction between Et3PAuCl and DTT in CDCl3 
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Table 3: Location of peaks on 1H NMR spectrum and indicated protons 
 Et3PAuCl DTT Et3PAuCl + DTT 
Peak Location 
(ppm) 
Proton 
Designation 
Location 
(ppm) 
Proton 
Designation 
Location 
(ppm) 
Proton 
Designation 
1 1.19 a,d,f 1.49 a,h 1.19 a,d,f 
(Et3PAuCl) 
2 1.54 Water 2.73 b,g 1.49-1.56 a,h (DTT) 
and water 
3 1.83 b,c,e 3.66 c,e 1.83 b,c,e 
(Et3PAuCl) 
4 5.29 Impurity 5.29 Impurity 2.62-2.74 b,g (DTT) 
5 7.25 CDCl3 7.25 CDCl3 3.66 c,e (DTT) 
6 - - - - 5.29 Impurity 
7 - - - - 7.25 CDCl3 
 
 
 
 
Figure 62: Proton labeling from left to right: Et3PAuCl and DTT 
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Results and Discussion: Experiment I was carried out to compare the reaction between 
DTT and Et3PAuCl (Experiment H) and DTT and Et3PAuSpy (Experiment I). Et3PAuCl 
and reduced DTT are not UV-Vis active, and therefore show no absorbance. The goal of 
the experiment was to observe using UV-Vis the possible appearance of a peak to 
indicate the formation of a product. No such peak appeared. The 1H NMR data showed 
that the reaction solution of DTT and Et3PAuCl showed all of the peaks that DTT and 
Et3PAuCl showed separately and no chemical shifts were observed. The peak at 5.29 
ppm was a methylene chloride peak that showed reagent bottle contamination. It seems 
plausible from UV and 1H NMR data that Et3PAuCl and DTT do not react. Since 
Et3PAuCl and DTT would have reacted through a simple ligand substitution, it seems like 
Et3PAuSpy and DTT do not go through a ligand substitution mechanism.  
Furthermore, it is possible that the DTT forms a complex with Et3PAuCl, whereby it 
links two of the molecules together (Figure 63)43. However, since there is no indication of 
chemical shifts, there is no reason to think the dimer was formed.  
 
Figure 63: Possible product of the reaction between Et3PAuCl and DTT 
 
It is useful to mention that dithioerythritol (DTE), an isomer of DTT was successfully 
reacted with Et3PAuCl in a 50/50 mixture of ethanol and water under vigorous stirring to 
form a white precipitate in one study43. An indicator that the reaction occurred was the 
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sudden acidification of the solution43. It is possible that Et3PAuCl may react with DTT 
under likewise conditions. 
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DISCUSSION 
	
	
Approximately 20% of all human proteins are predicted to contain disulfide bonds4. With 
this abundance in the human organism, it is important to study thiol-disulfide exchange 
reactions using biological models to gain insight into how disease-specific drugs may be 
interacting with proteins in the body. By looking at how gold thiolates interact with 
protein disulfides using insulin as a model protein disulfide, this experiment was able to 
look at how gold thiolates might be interacting with biological disulfides in a gold 
thiolate-disulfide exchange reaction.  
 
The study was started by replicating two experiments performed by the Lees research 
group, namely the reaction between 4-mercaptobenzoic acid, DTT and insulin compared 
to the reaction between DTT and insulin. The method of data collection used was UV-Vis 
spectroscopy, but it was used to observe light scatter at 650 nm, instead of the usual 
absorbance method. When the disulfide bonds in insulin are reduced, the two chains of 
insulin break apart, forming a colloidal suspension. This suspension scatters light at 650 
nm, which provides a curve that shows an initial lag time (which can be attributed to the 
particles not having yet reached a critical concentration at which they start aggregation), 
followed by a steady increase in light scatter (aggregation), which is directly proportional 
to the extent to which the insulin disulfide bonds have been broken. After reaching a 
certain maximum, the particles become too dense to stay in the colloidal suspension and 
sink to the bottom, which is why the rate of particle formation decreases after reaching a 
maximum. The relative rate that was acquired during this study (approximately 1.7) was 
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close to the value reported by Lees of 1.6, showing that 4-mercaptobenzoic acid catalyzes 
the reaction between DTT and insulin. This was a good starting point for the study, and 
the results are depicted in Experiments A and B. The next step of the study was to see if 
4-mercaptobenzoic acid would break the disulfide bonds in insulin without the assistance 
of DTT. Experiment C showed no reaction as monitored by UV-Vis over 24 hours. This 
suggested that either 4-mercaptobenzoic acid does not react with insulin, or that the lag 
time of the reaction is very long and is beyond the scope of the 24 hours that was 
dedicated to the reaction.  
 
The next step of the study was to try a gold thiolate in the reaction between DTT and 
insulin to see if the gold compound would have the same effect as the aromatic thiol used 
previously (4-mercaptobenzoic acid). However, when synthesized, Et3PAuSba was not 
soluble in phosphate buffer, which was the solvent system that was being used for the 
experiments. Thus, it became necessary to change the thiol that was being investigated, 
so that once the gold thiolate that had the thiol moiety attached to it was synthesized, it 
would be soluble in phosphate buffer. This would ensure that all reactants were fully 
soluble in the solvent and any precipitation observed would be caused by the breaking of 
the disulfide bonds in insulin and the formation of the colloidal suspension of α and β 
chain particles. The thiol that was picked as a replacement was 2-mercaptopyridine, 
which was available in lab, and it was known that Et3PAuSpy was soluble in phosphate 
buffer. Experiment D was conducted to observe the reaction between 2-
mercaptopyridine, DTT and insulin. A comparison was made between 2-
mercaptopyridine’s and 4-mercaptobenzoic acid’s effect on the rate of the reaction 
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between DTT and insulin. The graphs of these two experiments were nearly completely 
overlapping, suggesting similar results for effect on the rate of the reaction between DTT 
and insulin.  
 
The next step of the study was to see what effect the gold thiolate would have on the rate 
of the reaction between DTT and insulin. This was the purpose of Experiment E. The 
graph obtained showed an initial increase, followed by a drastic decrease in slope, yet 
still increasing for some time and then another drastic increase in slope. This kind of 
graph was a surprise, because it indicated the possibility that there could be several 
mechanisms at work when combining Et3PAuSpy, DTT and insulin. As was found by 
Experiments E and F, which looked at the reaction between Et3PAuSpy and insulin and 
the reaction between Et3PAuSpy and DTT respectively, these reactions were occurring by 
different mechanisms. The reaction between Et3PAuSpy and insulin produced the 
familiar colloidal suspension of α and β chain particles. The reaction between Et3PAuSpy 
and DTT was shown to produce 2-mercaptopyridine by both UV-Vis and 1H NMR. This 
suggests that the prediction about Experiment E (Et3PAuSpy, DTT and insulin), namely 
that there might be several competing mechanisms that give the different shape of the 
graph, might have merit.  
 
The next step in the study was to look at how Et3PAuCl would react with insulin. This 
was the purpose of Experiment H. The graph of the experiment showed the formation of 
a colloidal suspension, but several breaks in the graph suggest either instrument 
malfunction or possibly interesting particle formation dynamics. Since the experiment 
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was not replicated, it is hard to say which of those is more plausible. The reproducibility 
aspect is addressed further below. The observation that Et3PAuCl reacts with insulin 
makes analysis harder, since Et3PAuCl would not break the disulfide bonds by thiol-
disulfide exchange and would instead want to participate in a ligand-substitution reaction. 
This makes the results of this experiment interesting, because it suggests that Et3PAuCl is 
interacting with other amino acids in insulin, possibly such donor atom-containing amino 
acids as histidine. Lastly, Experiment I was conducted to look at the possible reaction 
between Et3PAuCl and DTT. Neither UV-Vis nor 1H NMR showed that a reaction was 
occurring. It is possible that the conditions in which the reaction was conducted were not 
optimal. DTT has to be deprotonated under basic conditions to react, and the UV-Vis 
reaction was conducted in methanol, which is technically an acid and a base at the same 
time. The 1H NMR reaction was carried out in deuterated chloroform, which is acidic 
because of the induction affects from the chloride groups. It is possible that DTT did not 
have a chance to be deprotonated and thus was not able to react. 
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CONCLUSION 
	
	
As far as specific conclusions that could be made from this study, they are as follows: 1) 
4-mercaptobenzoic acid and 2-mercaptopyridine catalyze the reaction between DTT and 
insulin, likely by the same mechanism, as supported by the Lees research group findings 
and UV-Vis data. 2) Et3PAuSpy seems to catalyze the reaction between DTT and insulin 
more so than the aromatic thiols, although it was also seen reacting with insulin directly, 
with no DTT present. Et3PAuSpy was also shown to react with DTT to produce 2-
pyridinethiol. As of now, it is unclear as to how the three of them react in solution. It is 
predicted that once all three are combined in solution, there are several competing 
mechanisms that occur together. 3) Et3PAuCl and insulin were shown to react. It is 
predicted that Et3PAuCl reacts with donor atom-containing amino acids in insulin such as 
histidine, which could cause precipitation of insulin molecules.   
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FUTURE WORK 
	
An important point to consider is that while these studies are concerned with observing 
the reaction between insulin and a variety of thiols and thiolates, the reaction happens in a 
phosphate buffer system. One of the reasons this research is important is to facilitate the 
purification and correct refolding of disulfide-containing proteins from recombinant 
inclusion bodies (insoluble protein aggregates)44. However, the folding of inclusion 
bodies of disulfide-containing proteins is typically performed in the presence of a 
denaturant such as guanidine hydrochloride or urea, while this research was not 
conducted with a denaturant present44. It is, however, important to point out that studies 
on the reaction between RNase A and small ortho- and meta-substituted aromatic thiols 
in the presence of denaturants provided 100% recovery of active protein without 
significant alteration of protein-folding rates44. It would be interesting to see whether 
gold thiolates would have the same effect. 
 
Additionally, the experiments performed in this study have not been replicated to the 
extent as to be able to talk about error and reproducibility. The first two experiments 
(Experiment A: 4-mercaptobenzoic acid, DTT and insulin; Experiment B: DTT and 
insulin) have been done by the Lees research group, and their relative rate of 1.6 showed 
that 4-mercaptobenzoic acid catalyzed the breaking of the insulin disulfide bonds, 
therefore increasing the rate of the formation of the colloidal suspension. The results of 
Experiments A and B give an approximate relative rate of 1.7, which is close to the Lees 
relative rate of 1.6. This suggests that Experiments A and B reproduced the results 
acquired by the Lees research group. However, to be certain that the conclusions of this 
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study are valid, each experiment would need to be replicated at least 3-4 times to be able 
to calculate the mean rate and the standard deviation from the mean to be able to discuss 
precision and reproducibility. Especially experiments that had unexpected artifacts or 
outcomes (such as Experiment H, Figure 56) would need to be replicated to see whether 
those artifacts (such as breaks in the graph) are due to improper instrumentation function 
or are indications of complicated mechanisms that would warrant further study of the 
reaction. The reaction of Et3PAuCl with DTT was also most likely conducted under 
improper conditions, as DTT has to be deprotonated under basic conditions, while the 
two solvents used for the UV-Vis and 1H NMR experiments were methanol and 
deuterated chloroform respectively. This could provide nonideal conditions for this 
reaction and it might thus be possible to react Et3PAuCl with DTT under different 
conditions. 
 
The factors that have been shown to be important advantages for protein folding catalysts 
as indicated by Lees are as follows: 
1) Low thiol pKa (strongly acidic thiol, weakly basic thiolate-close to physiological 
pH), a pKa of approximately 1 unit less than the pH of the solution has been 
found to be optimal for protein folding, with increased thiolate reactivity4 
2) Low reduction potential (allows the catalyst to exist as a nearly 50:50 mixture of 
thiol and disulfide for efficient protein folding)4 
3) Dithiol over a monothiol (dithiols discourage forming long-lived mixed disulfides 
between the folding catalyst and the protein of interest) 
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4) Aromatic thiols increase the rate of folding by at least three times as opposed to 
aliphatic thiols 
 
In developing more efficient protein folding catalysts it is important to keep these factors 
in mind. In the case of gold thiolates, a possible development of an aromatic gold dithiol 
with a low pKa might be advantageous for further studies in regard to the redox buffer.  
 
A look at the different variables that can be changed in the study is also warranted. 
Studies can be designed that change variables that were kept constant during this study 
but might shed some light on the results. For example, it might be interesting to look at 
the way the rate of formation of the colloidal suspension (the rate of disulfide bond 
breakage) changes when the reaction is stirred, when the temperature is changed or when 
the pH is changed (keeping in mind that insulin is only soluble in a buffer of pH 6-8). 
These studies could account for such things as diffusion (since the reactions were not 
stirred in this experiment) and the mean aggregation rate could be acquired instead of the 
initial rate.   
 
Insulin is used as a model protein because it has three disulfide bonds and is readily 
commercially available; however, the study can be opened to other proteins containing 
disulfides. Other methods of data collection might also prove more optimal than light 
scatter, such as Particle Size Distribution, which could shed some light on such reactions 
as Et3PAuSpy, DTT and insulin, which is predicted to react in several different 
competing mechanisms (Et3PAuSpy reacts both with DTT and insulin, and DTT reacts 
with insulin as well, all react by different mechanisms). Other useful techniques could be 
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HPLC (to look at the formation of oxidized DTT) or mass spectrometry, which would 
further the studies previously discussed in the Introduction, and in which Me3PAu+ 
proved a very promising compound for the breaking of disulfide bonds in gas-phase 
reactions. 
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